Rare disease to blockbuster
Signs of the birth of blockbusters from drugs for rare diseases. A great achievement for Alnylam in the US. Successful expansion of siRNA drug indications from familial to age-related diseases. See analysis below.
https://miyata-bio.net/column/0000356/
この記事が気に入ったらサポートをしてみませんか？